Issue 74, 2014

Development of a highly potent, selective, and cell-active Inhibitor of cysteine cathepsin L–A hybrid design approach

Abstract

A hybrid-design approach is undertaken to develop a highly potent and selective inhibitor of human cathepsin L. Studies involving human breast carcinoma MDA-MB-231 cells establish that this inhibitor can successfully block intracellular cathepsin L activity, and retard the cell-migratory potential of these highly metastatic cells.

Graphical abstract: Development of a highly potent, selective, and cell-active Inhibitor of cysteine cathepsin L–A hybrid design approach

Supplementary files

Article information

Article type
Communication
Submitted
26 May 2014
Accepted
27 Jul 2014
First published
28 Jul 2014

Chem. Commun., 2014,50, 10875-10878

Development of a highly potent, selective, and cell-active Inhibitor of cysteine cathepsin L–A hybrid design approach

D. Dana, S. De, P. Rathod, A. R. Davalos, D. A. Novoa, S. Paroly, V. M. Torres, N. Afzal, R. S. Lankalapalli, S. A. Rotenberg, E. J. Chang, G. Subramaniam and S. Kumar, Chem. Commun., 2014, 50, 10875 DOI: 10.1039/C4CC04037F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements